Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants-Reference-Cited by-同舟云学术

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Published:2021-08-13 Issue:6556 Volume:373 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Wang Lingshu¹^ORCID,Zhou Tongqing¹^ORCID,Zhang Yi¹^ORCID,Yang Eun Sung¹^ORCID,Schramm Chaim A.¹,Shi Wei¹,Pegu Amarendra¹^ORCID,Oloniniyi Olamide K.¹^ORCID,Henry Amy R.¹,Darko Samuel¹^ORCID,Narpala Sandeep R.¹^ORCID,Hatcher Christian¹,Martinez David R.²³^ORCID,Tsybovsky Yaroslav⁴,Phung Emily¹^ORCID,Abiona Olubukola M.¹^ORCID,Antia Avan¹,Cale Evan M.¹^ORCID,Chang Lauren A.¹^ORCID,Choe Misook¹^ORCID,Corbett Kizzmekia S.¹^ORCID,Davis Rachel L.¹,DiPiazza Anthony T.¹^ORCID,Gordon Ingelise J.¹^ORCID,Hait Sabrina Helmold¹^ORCID,Hermanus Tandile⁵⁶,Kgagudi Prudence⁵⁶,Laboune Farida¹,Leung Kwanyee¹^ORCID,Liu Tracy¹,Mason Rosemarie D.¹^ORCID,Nazzari Alexandra F.¹^ORCID,Novik Laura¹^ORCID,O’Connell Sarah¹,O’Dell Sijy¹,Olia Adam S.¹^ORCID,Schmidt Stephen D.¹^ORCID,Stephens Tyler⁴,Stringham Christopher D.¹^ORCID,Talana Chloe Adrienna¹^ORCID,Teng I-Ting¹,Wagner Danielle A.¹^ORCID,Widge Alicia T.¹^ORCID,Zhang Baoshan¹^ORCID,Roederer Mario¹^ORCID,Ledgerwood Julie E.¹,Ruckwardt Tracy J.¹^ORCID,Gaudinski Martin R.¹^ORCID,Moore Penny L.⁵⁶^ORCID,Doria-Rose Nicole A.¹^ORCID,Baric Ralph S.²³^ORCID,Graham Barney S.¹^ORCID,McDermott Adrian B.¹^ORCID,Douek Daniel C.¹,Kwong Peter D.¹^ORCID,Mascola John R.¹^ORCID,Sullivan Nancy J.¹^ORCID,Misasi John¹^ORCID

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

2. Department of Epidemiology, UNC Chapel Hill School of Public Health, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

3. Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

4. Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

5. National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.

6. SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Abstract

Defenses against SARS-CoV-2 variants Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV

Funder

National Institutes of Health

Frederick National Laboratory for Cancer Research

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference52 articles.

1. Johns Hopkins Coronavirus Resource Center COVID-19 Map; https://coronavirus.jhu.edu/map.html.

2. A new coronavirus associated with human respiratory disease in China

3. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

4. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

5. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain;Structure;2024-02

2. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants;Nature Communications;2024-01-29

3. Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates;Science Translational Medicine;2024-01-03

4. Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates;Nature Communications;2023-12-02

5. Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants;Immunity;2023-12